Health Statutes Amendment Act, 2024 (No. 2)

On December 5, 2024, the Alberta Legislature passed three bills that collectively represented the most direct legislative assertion of sex-based rights for children and women anywhere in Canada. One of those bills — the Health Statutes Amendment Act, 2024 (No. 2), introduced as Bill 26 — restricted the medical transition of minors, prohibiting puberty blockers, cross-sex hormones, and gender-affirming surgeries for anyone under 18 experiencing gender dysphoria.

Within 24 hours, it was in court.

That speed — legislation passed on December 5, litigation filed on December 6 — tells you something about the stakes both sides believe are involved. For the organizations challenging the law, Bill 26 represented an unconstitutional denial of healthcare to transgender youth. For the Alberta government and the advocates who supported the legislation, it represented a long-overdue application of the precautionary principle to a pediatric medical intervention with no long-term safety data, no randomized controlled trials, and an accelerating international consensus that the evidence base was, in the words of the UK's landmark Cass Review, remarkably weak.

As of May 2026, Bill 26 is in force. The injunction that briefly blocked it has been ended. The Charter challenge has been narrowed to a federalism argument that a Court of King's Bench denied in May 2026. An appeal is being pursued. The legislation stands.

This is the story of what Bill 26 does, why Alberta passed it, what happened when the courts intervened, and why the government held the line.

The Rise of Pediatric Gender Medicine in Canada

To understand Bill 26, you need to understand what it is responding to.

Prior to roughly 2012, gender dysphoria — the clinical condition of experiencing distress due to incongruence between one's biological sex and internal sense of identity — was rare in children and adolescents, occurred predominantly in natal males, and typically resolved by adulthood without medical intervention. The standard clinical approach was watchful waiting: psychological support, careful monitoring, and a recognition that the large majority of gender-dysphoric children would, by adulthood, come to identify with their biological sex, often as gay or lesbian adults.

That model changed rapidly. Between 2012 and 2020, referrals to pediatric gender clinics in Canada, the United Kingdom, the United States, Australia, and across Europe increased by factors of ten to forty, depending on the country and clinic. More significantly, the demographics of that population inverted: what had been a condition presenting predominantly in natal males became one presenting predominantly in natal females — adolescent girls, typically in their early to mid-teens, with no prior history of childhood gender dysphoria.

In Canada, the change was documented. Dr. Margaret Lawson, endocrinologist at the Children's Hospital of Eastern Ontario, stated publicly in 2019 that adolescent natal females then comprised approximately 75% of the patients her clinic was seeing. The clinical response to this surge was not caution. It was affirmation. Driven by advocacy organizations, influenced by the World Professional Association for Transgender Health's Standards of Care, and shaped by a cultural environment in which questioning a young person's declared gender identity was treated as harmful, Canadian gender clinics moved rapidly toward an affirmation model: social transition first, then medical intervention on a pathway that was described to families as reversible but that, in practice, functioned as a near-universal conveyor belt toward permanent medicalization.

Bill 26 is the Alberta legislature's response to that model.

What Bill 26 Actually Says

The Health Statutes Amendment Act, 2024 (No. 2) amended several Alberta health statutes to restrict gender-affirming medical interventions for minors. Its operative provisions are clear.

On puberty blockers and cross-sex hormones: Bill 26 prohibited regulated health professionals in Alberta from prescribing puberty-suppressing drugs or cross-sex hormones to individuals under 18 for the purpose of treating gender dysphoria, regardless of parental consent or the minor's expressed wishes.

On surgery: Bill 26 prohibited gender-affirming surgeries on anyone under 18, including mastectomies performed for gender affirmation and genital surgeries.

On existing patients: The legislation included transition provisions for minors already receiving treatment at the time of passage. Those patients were not immediately cut off, and some categories of youth remain eligible under the legislation's exceptions.

On the 16 and 17 age range: For patients aged 16 and 17, Bill 26 created a limited exception allowing hormone treatment with the combined approval of a parent, a physician, and a psychologist — a three-party consent requirement that reflects recognition that older adolescents occupy a distinct position, while asserting that self-declaration alone is insufficient for irreversible medical intervention.

What Bill 26 does not say: The legislation does not prohibit psychological support, counselling, or any non-medical approach to addressing gender dysphoria. It does not prevent clinicians from discussing gender identity with patients. It does not prohibit social transition. Bill 26 restricts the administration of specific drugs and surgeries. It mandates nothing about how clinicians or families discuss gender identity.

The Medical Evidence: What the Cass Review Found

The political debate over pediatric gender medicine in Alberta did not occur in an evidential vacuum. It occurred against the background of the most comprehensive independent review of the clinical evidence ever conducted.

In April 2024, Dr. Hilary Cass released the final report of the Independent Review of Gender Identity Services for Children and Young People — a four-year review commissioned by NHS England and conducted with the assistance of the University of York's evidence synthesis team. Its findings were unambiguous.

On puberty blockers, the Review found the evidence for their benefits was of very low certainty and that the claim that they are fully reversible — made routinely to families as part of the informed consent process — was not supported by the available research. The Review noted that the majority of children who begin puberty blockers proceed to cross-sex hormones, raising serious questions about the treatment pathway's actual clinical function.

On cross-sex hormones, the Review found similarly weak evidence of benefit and identified significant gaps in long-term safety data, particularly regarding fertility, bone density, cardiovascular health, and neurological development.

On the demographic shift, the Review acknowledged that the rapid increase in adolescent females presenting with gender dysphoria represented an unexplained clinical phenomenon that existing research had not adequately characterized, and explicitly cautioned against applying clinical protocols developed for a largely male patient population to the predominantly female population now presenting to gender clinics.

The Review's overall conclusion was that pediatric gender medicine had developed by inverting the normal evidentiary requirements for clinical practice: rather than establishing safety and efficacy before widespread adoption, gender-affirming interventions had been adopted widely on the basis of advocacy and limited case series, with the evidence review coming afterward and finding the foundation inadequate.

Alberta's Bill 26 reflects the Cass Review's central finding: where the evidence is inadequate, the precautionary principle requires caution, not continuation.

The International Context

The Cass Review did not emerge in isolation. Its conclusions are consistent with a parallel movement in clinical policy across multiple countries that had been earlier and more aggressive in adopting the gender-affirmation model.

Sweden's National Board of Health and Welfare moved in 2022 to restrict puberty blockers and cross-sex hormones for minors to exceptional cases, following an internal review that found the risks outweighed the benefits for most patients. Finland's Council for Choices in Health Care issued similar guidance in 2020, concluding that gender dysphoria in minors should be treated primarily through psychological means, with medical intervention reserved for exceptional circumstances and only after thorough assessment. Denmark, Norway, and Iceland have each moved in similar directions. The United Kingdom, following the Cass Review, announced the closure of the Tavistock clinic and the development of a new, regionally distributed model emphasizing holistic assessment over medical affirmation.

The Canadian policy response to this international shift has been the opposite of Alberta's. No other Canadian province has legislated restrictions on pediatric gender medicine. Several have actively expanded access. The federal government has not initiated any independent evidence review comparable to the Cass Review.

Alberta, by passing Bill 26, aligned itself with the international clinical direction. That alignment is proving, in the weight of accumulating evidence, to be on the right side of the science.

Why This Matters for Women and Girls

Pediatric gender medicine is not a gender-neutral issue. The population most affected by the clinical model Bill 26 restricts is overwhelmingly female.

The documented shift in gender clinic demographics — from a predominantly male patient population to a predominantly female one — has occurred simultaneously across multiple countries, in different cultural contexts, with different healthcare systems. The one common factor is the cultural and digital environment in which adolescent girls are developing: an environment saturated with gender identity content on social media, in school curricula, and in peer networks.

Researchers and clinicians who have studied this population have documented patterns inconsistent with the classical model of gender dysphoria. Many of the adolescent females presenting to gender clinics have comorbid mental health conditions — depression, anxiety, eating disorders, a history of trauma or sexual abuse, autism spectrum conditions, or same-sex attraction experienced in an environment where being gay carries social stigma that being transgender does not.

The women who have detransitioned — who identified as transgender in adolescence, underwent medical transition, and subsequently returned to identifying with their biological sex — are among the most direct evidence of the harm this clinical model can produce. They describe being affirmed into a medical pathway before the underlying issues in their lives had been identified or addressed. They describe being given testosterone and mastectomies as teenagers, by clinicians who asked few questions, and discovering in their twenties that the transition had not resolved the distress it was supposed to treat.

Bill 26 exists, in part, because of these women.

The Charter Challenge, the Injunction, and Bill 9

On December 6, 2024, Egale Canada Human Rights Trust, Skipping Stone Foundation, and several Alberta families filed applications challenging Bills 26, 27, and 29 under the Canadian Charter of Rights and Freedoms. On June 27, 2025, Justice Colin Feasby of the Court of King's Bench of Alberta granted an injunction suspending the Bill 26 prohibition on puberty blockers and cross-sex hormones for minors, pending the determination of the Charter challenge. The injunction was not a ruling on the merits.

The Alberta government appealed the injunction and simultaneously moved to neutralize it legislatively. On November 18, 2025, the government introduced Bill 9 — the Protecting Alberta's Children Statutes Amendment Act, 2025. Bill 9 passed on December 10, 2025.

Bill 9 did three things. It re-enacted the substance of Bills 26, 27, and 29. It invoked section 33 of the Canadian Charter of Rights and Freedoms — the notwithstanding clause — shielding the legislation from Charter review under sections 2 and 7 through 15 for a renewable five-year period. And it suspended the application of the Alberta Bill of Rights and the Alberta Human Rights Act to the legislation in perpetuity — a scope of override broader than any previous invocation of the notwithstanding clause in Alberta's history.

On December 18, 2025, the Alberta government formally ended the injunction against Bill 26 on the basis of the notwithstanding clause invocation. Bill 26 came into force. Access to puberty blockers and cross-sex hormones for gender dysphoria treatment was restricted for minors in Alberta, with exceptions remaining for some categories of youth under the legislation's provisions.

Premier Danielle Smith characterized the decision plainly: "This government does not turn to the notwithstanding clause unless the stakes warrant it, and in this case, the stakes could not be higher."

The Federalism Challenge and Where Things Stand in May 2026

The notwithstanding clause shields legislation from Charter review — but not from all constitutional challenges. Egale Canada and Skipping Stone, working with lawyers from McCarthy Tétrault LLP, amended their legal challenge to pursue two remaining arguments.

The first is a claim for declaratory relief: even where a court cannot strike down legislation protected by the notwithstanding clause, it may still be able to declare that the legislation violates Charter rights. The Supreme Court of Canada is hearing cases in 2026, including the UR Pride case from Saskatchewan, that will determine whether this power of declaratory relief exists when the notwithstanding clause has been invoked.

The second is a federalism argument. Egale's legal team argues that Bill 26 is unconstitutional because the province of Alberta is improperly seeking to criminalize healthcare — a matter of criminal law that falls under exclusive federal jurisdiction. The argument draws on a 1993 Nova Scotia case challenging provincial legislation that restricted abortion access on jurisdictional grounds.

In May 2026, the Court of King's Bench of Alberta denied the application to amend the legal challenge to include these new arguments. Egale Canada has stated it intends to appeal that decision.

As of May 21, 2026, Bill 26 remains in force in Alberta. The legal challenge continues but has been significantly narrowed. The legislation restricting gender-affirming medical care for minors in Alberta is operative law.

Conclusion: Precaution Is Not Cruelty

The framing of Bill 26 as anti-trans healthcare rests on a contested premise: that puberty blockers, cross-sex hormones, and surgeries administered to adolescents constitute healthcare in the established sense — evidence-based, safety-monitored, and indicated for the population receiving them.

The Cass Review found that premise inadequate. The international clinical movement away from pediatric medical affirmation reflects a similar finding. The testimony of detransitioners — young women who were medicalized as teenagers and who are now navigating the consequences in their adult bodies — provides human evidence of the institutional failure the statistics describe.

Bill 26 does not tell gender-dysphoric children that their distress is not real, that they are not worthy of support, or that they do not deserve care. It says that specific medical interventions administered to children at scale, without adequate evidence of safety or long-term benefit, should not be administered to children in Alberta until that evidence exists.

That is not cruelty. It is what responsible clinical practice requires. And as of May 2026, it is the law in Alberta.